Dillon & Associates’s NeoGenomics NEO Stock Holding History

Dillon & Associates’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,000	Closed	-$272K	–	81
2021 Q4	$272K	Hold	8,000	–	–	0.05%	66
2021 Q3	$384K	Hold	8,000	–	–	0.07%	57
2021 Q2	$360K	Hold	8,000	–	–	0.07%	60
2021 Q1	$384K	Hold	8,000	–	–	0.08%	58
2020 Q4	$432K	Hold	8,000	–	–	0.09%	54
2020 Q3	$296K	Hold	8,000	–	–	0.07%	57
2020 Q2	$248K	Hold	8,000	–	–	0.07%	62
2020 Q1	$224K	Hold	8,000	–	–	0.08%	61
2019 Q4	$232K	Buy	+8,000	New	+$191K	0.06%	64

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Dillon & Associates's NEO Position: Q1 2022 in Review

Dillon & Associates sold out of NeoGenomics (NEO) in Q1 2022, closing a stake of 8,000 shares — an estimated $272K sold.

Dillon & Associates first reported a position in NEO in Q4 2019 and held it in 9 quarters. The position peaked at $432K in Q4 2020. 279 funds tracked by Wall St. Rank hold NEO as of Q1 2022.

Dillon & Associates reported no remaining NeoGenomics position as of Q1 2022 after selling out during the quarter.
Dillon & Associates sold 8,000 NeoGenomics shares in Q1 2022, an estimated $272K.
Dillon & Associates first reported a position in NeoGenomics in Q4 2019 and held it in 9 quarters.
Dillon & Associates's NeoGenomics position peaked at $432K in Q4 2020.
279 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2022.

Based on Dillon & Associates's 13F filing for Q1 2022, filed 6 May 2022.